Latest Royalty Income News

Encore Minerals has approved development of the Windarra Tailings Project, triggering a $400,000 payment to Maritana Minerals and preserving the company’s exposure to future gold production through royalties. Encore will carry the project’s development and operating costs, although key execution milestones remain ahead.

Red Hill Minerals has more than doubled FY2026 net profit to A$20.1 million as its Onslow Iron royalty delivered A$28.8 million in income. The ASX-listed miner declared a fully franked final dividend of 10.8 cents per share, taking FY2026 distributions to 22.4 cents per share.

Fitzroy River Corporation reported a modest loss for FY26, with a key highlight being a $12.27 million disputed payment from Endura Mining related to its Snowy River Gold Project royalty. The company has initiated court proceedings in New Zealand to clarify the validity of this buyout option while exploring potential sale of its Bowdens Silver royalty.

Talisman Mining secures A$4 million through a strongly supported placement, including significant board participation, to fund exploration and new project opportunities in gold-rich NSW and Western Australia.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Strata Investment Holdings delivered a £16.48 million comprehensive profit for H1 2026, driven by a strong revaluation of its investment portfolio and maiden royalty income from Botswana copper assets.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

Oakridge International Limited has reversed its fortunes with a 42% revenue increase to $3.45 million and a return to profitability in FY2026, driven by healthcare technology sales and strategic platform enhancements.

Brisbane Broncos expect a 33% increase in half-year net profit before tax to $11.57 million, driven by higher crowd attendance and merchandise sales despite reduced ARLC funding and rising costs.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

Galilee Energy has agreed to sell its Glenaras Gas Project subsidiary to Novus Energy, freeing up capital and management focus to accelerate its US Gulf Coast oil and gas ambitions while retaining a royalty interest in Glenaras.